Latest NCPE Advice

Acoramidis (Beyonttra®) HTA ID: 25017

Assessment Status Rapid Review Complete
HTA ID 25017
Drug Acoramidis
Brand Beyonttra®
Indication Acoramidis (Beyonttra®) is indicated for wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Assessment Process
Rapid review commissioned 05/03/2025
Rapid review completed 03/04/2025
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of acoramidis compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Further information on this process may be found here.

Further information on the status of this decision may be found here.

Alectinib (Alecensa®). HTA ID: 24017

Assessment Status Rapid Review complete
HTA ID 24017
Drug Alectinib
Brand Alecensa®
Indication As adjuvant treatment following complete tumour resection for adult patients with ALK-positive NSCLC at high risk of recurrence.
Assessment Process
Rapid review commissioned 24/05/2024
Rapid review completed 02/07/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of alectinib for this indication compared with the current standard-of-care, on the basis of the proposed price relative to currently available therapies.

Amivantamab (Rybrevant®). HTA ID 24044

Assessment Status Rapid Review Complete
HTA ID 24044
Drug Amivantamab
Brand Rybrevant®
Indication Amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI)
Assessment Process
Rapid review commissioned 25/10/2024
Rapid review completed 13/12/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care.

Andexanet alfa (Ondexxya®). HTA ID: 20014

Assessment Status NCPE Assessment Process Complete
HTA ID 20014
Drug Andexanet alfa
Brand Ondexxya®
Indication For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.  
Assessment Process
Rapid review commissioned 12/03/2020
Rapid review completed 23/04/2020
Rapid review outcome A full HTA is required to assess the clinical effectiveness and cost-effectiveness of andexanet alfa compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/04/2020
Pre-submission consultation with Applicant 26/01/2021
Full submission received from Applicant 26/10/2021
Preliminary review sent to Applicant 13/12/2021
NCPE assessment re-commenced 31/01/2022
Factual accuracy sent to Applicant 27/04/2022
NCPE assessment re-commenced 04/05/2022
NCPE assessment completed 27/05/2022
NCPE assessment outcome The NCPE recommends that andexanet alfa (Ondexxya®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations April 2023.

Apalutamide (Erleada®). HTA ID: 20010

Assessment Status NCPE Assessment Process Complete
HTA ID 20010
Drug Apalutamide
Brand Erleada®
Indication For the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy.
Assessment Process
Rapid review commissioned 26/02/2020
Rapid review completed 23/03/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of apalutamide for this indication compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/03/2020
Pre-submission consultation with Applicant 15/06/2020
Full submission received from Applicant 20/04/2021
Preliminary review sent to Applicant 01/11/2021
NCPE assessment re-commenced 26/11/2021
Factual accuracy sent to Applicant 09/02/2022
NCPE assessment re-commenced 17/02/2022
NCPE assessment completed 03/03/2022
NCPE assessment outcome The NCPE recommends that apalutamide (Erleada®) in combination with androgen deprivation therapy be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations March 2023.

Atezolizumab (Tecentriq®) for triple-negative breast cancer.

Assessment Status NCPE Assessment Process Complete
HTA ID -
Drug Atezolizumab
Brand Tecentriq®
Indication In combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
Assessment Process
Rapid review commissioned 03/07/2019
Rapid review completed 19/07/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/07/2019
Pre-submission consultation with Applicant 07/10/2019
Full submission received from Applicant 13/01/2020
Preliminary review sent to Applicant 05/05/2020
NCPE assessment re-commenced 29/05/2020
Factual accuracy sent to Applicant 06/08/2020
NCPE assessment re-commenced 14/08/2020
NCPE assessment completed 01/09/2020
NCPE assessment outcome The NCPE recommends that atezolizumab (Tecentriq®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations March 2022.

Avapritinib (Ayvakyt®). HTA ID: 25026

Assessment Status Rapid Review Complete
HTA ID 25026
Drug Avapritinib
Brand Ayvakyt®
Indication Avapritinib is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.
Assessment Process
Rapid review commissioned 24/03/2025
Rapid review completed 17/04/2025
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avapritinib compared with the current standard of care.

Avapritinib (Ayvakyt®). HTA ID: 25031

Assessment Status Rapid Review Complete
HTA ID 25031
Drug Avapritinib
Brand Ayvakyt®
Indication Avapritinib (Ayvakyt®) is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy.
Assessment Process
Rapid review commissioned 14/04/2025
Rapid review completed 15/05/2025
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avapritinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Further information on this process may be found here

Further information on the status of this decision may be found here

Avelumab (Bavencio®)

Assessment Status NCPE Assessment Process Complete
HTA ID -
Drug Avelumab
Brand Bavencio®
Indication For the treatment of adults with metastatic Merkel Cell Carcinoma.
Assessment Process
Rapid review commissioned 17/10/2017
Rapid review completed 21/11/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 22/11/2017
Pre-submission consultation with Applicant 11/12/2017
Full submission received from Applicant 16/03/2018
Preliminary review sent to Applicant 12/07/2018
NCPE assessment re-commenced 10/08/2018
Factual accuracy sent to Applicant 06/09/2018
NCPE assessment re-commenced 20/09/2018
NCPE assessment completed 08/10/2018
NCPE assessment outcome The NCPE recommends that avelumab (Bavencio®) for the treatment of metastatic Merkel Cell Carcinoma not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.

Technical Summary

The HSE has approved reimbursement “approval is restricted to second line” following confidential price negotiations May 2019.

Avelumab (Bavencio®). HTA ID: 19046

Assessment Status NCPE Assessment Process Complete
HTA ID 19046
Drug Avelumab
Brand Bavencio®
Indication Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.
Assessment Process
Rapid review commissioned 29/10/2019
Rapid review completed 02/01/2020
Rapid review outcome Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.
Full pharmacoeconomic assessment commissioned by HSE 07/01/2020
Pre-submission consultation with Applicant 18/02/2020
Full submission received from Applicant 31/07/2020
Preliminary review sent to Applicant 02/02/2021
NCPE assessment re-commenced 09/03/2021
Follow-up to preliminary review sent to Applicant 24/03/2021
NCPE assessment re-commenced 14/04/2021
Factual accuracy sent to Applicant 28/05/2021
NCPE assessment re-commenced 04/06/2021
NCPE assessment completed 23/06/2021
NCPE assessment outcome The NCPE recommends that avelumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013

Avelumab (Bavencio®). HTA ID: 21001

Assessment Status NCPE Assessment Process Complete
HTA ID 21001
Drug Avelumab
Brand Bavencio®
Indication As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy.
Assessment Process
Rapid review commissioned 25/01/2021
Rapid review completed 03/03/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avelumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/03/2021
Pre-submission consultation with Applicant 20/04/2021
Full submission received from Applicant 10/06/2021
Preliminary review sent to Applicant 28/09/2021
NCPE assessment re-commenced 22/10/2021
Factual accuracy sent to Applicant 29/11/2021
NCPE assessment re-commenced 06/12/2021
NCPE assessment completed 22/12/2021
NCPE assessment outcome The NCPE recommends that avelumab (Bavencio®), for first-line maintenance treatment of adult patients with bladder cancer who are disease free following platinum-based chemotherapy, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations September 2022.

Axicabtagene Ciloleucel (Yescarta®)

Assessment Status NCPE Assessment Process Complete
HTA ID -
Drug Axicabtagene Ciloleucel
Brand Yescarta®
Indication For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
Assessment Process
Rapid review commissioned 10/09/2018
Rapid review completed 18/10/2018
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axi-cel compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/10/2018
Pre-submission consultation with Applicant 03/12/2018
Full submission received from Applicant 20/03/2019
Preliminary review sent to Applicant 15/10/2019
NCPE assessment re-commenced 13/11/2019
Follow-up to preliminary review sent to Applicant 13/12/2019
NCPE assessment re-commenced 20/12/2019
Factual accuracy sent to Applicant 04/02/2020
NCPE assessment re-commenced 11/02/2020
NCPE assessment completed 21/02/2020
NCPE assessment outcome The NCPE recommend that axicabtagene ciloleucel (Yescarta®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations April 2022.

Axicabtagene ciloleucel (Yescarta®). HTA ID: 22066

Assessment Status NCPE Assessment Process complete
HTA ID 22066
Drug Axicabtagene ciloleucel
Brand Yescarta®
Indication For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Assessment Process
Rapid review commissioned 27/09/2022
Rapid review completed 10/11/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axicabtagene ciloleucel compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/11/2022
Pre-submission consultation with Applicant 21/03/2023
Full submission received from Applicant 06/09/2023
Preliminary review sent to Applicant 01/03/2024
NCPE assessment re-commenced 28/03/2024
Factual accuracy sent to Applicant 31/07/2024
NCPE assessment re-commenced 08/08/2024
NCPE assessment completed 16/10/2024
NCPE assessment outcome The NCPE recommends that axicabtagene ciloleucel (Yescarta ®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

Aztreonam-avibactam (Emblaveo®). HTA ID: 24037

Assessment Status Rapid Review complete
HTA ID 24037
Drug Aztreonam-avibactam
Brand Emblaveo®
Indication For the treatment of the following infections in adult patients: • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritis. Aztreonam-avibactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
Assessment Process
Rapid review commissioned 23/09/2024
Rapid review completed 25/10/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that aztreonam-avibactam not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Baricitinib (Olumiant®) for atopic dermatitis. HTA ID: 21050

Assessment Status Rapid Review complete
HTA ID 21050
Drug Baricitinib
Brand Olumiant®
Indication Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 09/11/2021
Rapid review completed 16/12/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

Baricitinib (Olumiant®) for moderate to severe atopic dermatitis. HTA ID: 20056

Assessment Status Rapid Review complete
HTA ID 20056
Drug Baricitinib
Brand Olumiant®
Indication Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 14/12/2020
Rapid review completed 28/01/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Bazedoxifene (Conbriza®)

Assessment Status Rapid Review complete
HTA ID -
Drug Bazedoxifene
Brand Conbriza®
Indication Treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.
Assessment Process
Rapid review commissioned 20/09/2011
Rapid review completed 02/11/2011
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.

Beclometasone /formoterol (Fostair®) for COPD. HTA ID 23037

Assessment Status Rapid Review Complete
HTA ID 23037
Drug Beclometasone /formoterol
Brand Fostair®
Indication Beclometasone / formoterol (Fostair®) for COPD. HTA ID 23037 Symptomatic treatment of patients with severe chronic obstructive pulmonary disease [COPD] (forced expiratory volume [FEV1] <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Assessment Process
Rapid review commissioned 10/07/2023
Rapid review completed 20/07/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Fostair® for this indication not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®). HTA ID: 23033

Assessment Status Rapid Review Complete
HTA ID 23033
Drug Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide
Brand Trimbow®
Indication Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disorder (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).
Assessment Process
Rapid review commissioned 21/06/2023
Rapid review completed 19/07/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Trimbow® for this indication not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®). HTA ID: 23034

Assessment Status Rapid Review Complete
HTA ID 23034
Drug Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide
Brand Trimbow®
Indication Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year
Assessment Process
Rapid review commissioned 21/06/2023
Rapid review completed 19/07/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Trimbow® for this indication not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Beclometasone/formoterol (Fostair®) for asthma. HTA ID: 23038

Assessment Status Rapid Review Complete
HTA ID 23038
Drug Beclometasone/formoterol
Brand Fostair®
Indication Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA.
Assessment Process
Rapid review commissioned 10/07/2023
Rapid review completed 20/07/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Fostair® for this indication not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Bedaquiline (Sirturo®)

Assessment Status Rapid Review complete
HTA ID -
Drug Bedaquiline
Brand Sirturo®
Indication For use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Assessment Process
Rapid review commissioned 23/01/2015
Rapid review completed 20/02/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended

Full HTA not required.  The NCPE however recommend that if reimbursed that use of bedaquiline be subject to certain conditions.

Belatacept (Nulojix®)

Assessment Status Rapid Review complete
HTA ID -
Drug Belatacept
Brand Nulojix®
Indication In combination with corticosteroids and a mycophenolic acid (MPA), for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.
Assessment Process
Rapid review commissioned 15/11/2011
Rapid review completed 23/01/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

Belimumab (Benlysta®)

Assessment Status Rapid Review complete
HTA ID -
Drug Belimumab
Brand Benlysta®
Indication As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.
Assessment Process
Rapid review commissioned 11/08/2011
Rapid review completed 31/08/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

Not considered cost-effective due to non-submission of full pharmacoeconomic evaluation.

Belimumab (Benlysta®) for lupus nephritis. HTA ID: 23021

Assessment Status Rapid Review Complete
HTA ID 23021
Drug Belimumab
Brand Benlysta®
Indication Belimumab is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
Assessment Process
Rapid review commissioned 24/04/2023
Rapid review completed 16/05/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of belimumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

 

Belimumab (Benlysta®) for systemic lupus erythematosus. HTA ID: 23022

Assessment Status Rapid Review Complete
HTA ID 23022
Drug Belimumab
Brand Benlysta®
Indication Belimumab is indicated as add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.
Assessment Process
Rapid review commissioned 24/04/2023
Rapid review completed 29/05/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of belimumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

 

Benralizumab (Fasenra®)

Assessment Status Rapid Review complete
HTA ID -
Drug Benralizumab
Brand Fasenra®
Indication As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Assessment Process
Rapid review commissioned 15/01/2018
Rapid review completed 14/02/2018
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations; April 2019

Benralizumab (Fasenra®) Autoinjector. HTA ID: 20018

Assessment Status Rapid Review complete
HTA ID 20018
Drug Benralizumab
Brand Fasenra®
Indication As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Assessment Process
Rapid review commissioned 31/03/2020
Rapid review completed 28/04/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that benralizumab not be considered for reimbursement under high tech drug arrangements at the submitted price*.

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations October 2021

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)

Assessment Status Rapid Review complete
HTA ID -
Drug Bictegravir/emtricitabine/tenofovir alafenamide
Brand Biktarvy®
Indication Treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.
Assessment Process
Rapid review commissioned 30/04/2018
Rapid review completed 07/06/2018
Rapid review outcome Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations December 2018.

Bilastine (Drynol®)

Assessment Status Rapid Review complete
HTA ID -
Drug Bilastine
Brand Drynol®
Indication Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.
Assessment Process
Rapid review commissioned 10/03/2011
Rapid review completed 23/03/2011
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.

Bimekizumab (Bimzelx®). HTA ID: 25018

Assessment Status Rapid Review Complete
HTA ID 25018
Drug Bimekizumab
Brand Bimzelx®
Indication Bimekizumab (Bimzelx®) is indicated for the treatment of active moderate-to-severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
Assessment Process
Rapid review commissioned 06/03/2025
Rapid review completed 02/04/2025
Rapid review outcome A full HTA is not recommended. The NCPE recommends that bimekizumab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Further information on this process may be found here.

Further information on the status of this decision may be found here.

Bimekizumab (Bimzelx®). HTA ID: 25019

Assessment Status Rapid Review Complete
HTA ID 25019
Drug Bimekizumab
Brand Bimzelx®
Indication • For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs. • For the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
Assessment Process
Rapid review commissioned 06/03/2025
Rapid review completed 03/04/2025
Rapid review outcome A full HTA is not recommended. The NCPE recommends that bimekizumab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Further information on this process may be found here.

Further information on the status of this decision may be found here.

Birch bark extract (Filsuvez®). HTA ID: 23069

Assessment Status NCPE Assessment Process Complete
HTA ID 23069
Drug Birch bark extract
Brand Filsuvez®
Indication Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.
Assessment Process
Rapid review commissioned 10/11/2023
Rapid review completed 08/12/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of birch bark extract compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 18/12/2023
Pre-submission consultation with Applicant 23/04/2024
Full submission received from Applicant 15/10/2024
Preliminary review sent to Applicant 27/02/2025
NCPE assessment re-commenced 26/03/2025
Factual accuracy sent to Applicant 31/03/2025
NCPE assessment re-commenced 07/04/2025
NCPE assessment completed 14/04/2025
NCPE assessment outcome The NCPE recommends that birch bark extract (Filsuvez®) be considered for reimbursement if cost-effectiveness is improved*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regards to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Blinatumomab (Blincyto®) CD19+ BCP-ALL

Assessment Status Rapid Review complete
HTA ID -
Drug Blinatumomab
Brand Blincyto®
Indication As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL)  in first or second complete remission with minimal residual disease greater than or equal to 0.1%.
Assessment Process
Rapid review commissioned 19/08/2019
Rapid review completed 23/09/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price.*

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations February 2021.

Blinatumomab (Blincyto®) (paediatric ALL)

 

Assessment Status Rapid Review complete
HTA ID -
Drug Blinatumomab
Brand Blincyto®
Indication Treatment of paediatric patients aged 1 year and older with Philadelphia chromosome negative B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation
Assessment Process
Rapid review commissioned 15/01/2019
Rapid review completed 30/01/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of blinatumomab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations; May 2019

Blinatumomab (Blincyto®). HTA ID: 21031

Assessment Status Rapid Review complete
HTA ID 21031
Drug Blinatumomab
Brand Blincyto®
Indication Treatment of paediatric patients (aged 1 year plus) with high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia as part of consolidation therapy.
Assessment Process
Rapid review commissioned 05/07/2021
Rapid review completed 03/08/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations May 2022.

Boceprevir (Victrelis®)

Assessment Status NCPE Assessment Process Complete
HTA ID -
Drug Boceprevir
Brand Victrelis®
Indication As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.
Assessment Process
Full submission received from Applicant 19/08/2011
NCPE assessment completed 17/01/2012
NCPE assessment outcome Reimbursement Recommended

We consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.

Technical Summary

Bosentan (Tracleer®)

Assessment Status Rapid Review complete
HTA ID -
Drug Bosentan
Brand Tracleer®
Indication Treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
Assessment Process
Rapid review commissioned 27/06/2014
Rapid review completed 04/07/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended

Bosutinib (Bosulif®)

Assessment Status Rapid Review complete
HTA ID -
Drug Bosutinib
Brand Bosulif®
Indication Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Assessment Process
Rapid review commissioned 09/08/2013
Rapid review completed 18/09/2013
Rapid review outcome At the current price a full HTA would be required.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.

Brentuximab vedotin (Adcetris®)

Assessment Status NCPE Assessment Process Complete
HTA ID -
Drug Brentuximab vedotin
Brand Adcetris®
Indication Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Assessment Process
Rapid review commissioned 28/11/2012
Rapid review completed 21/12/2012
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full submission received from Applicant 16/09/2013
NCPE assessment completed 11/04/2014
NCPE assessment outcome Reimbursement not Recommended

December 2015

The HSE has approved reimbursement following confidential price negotiations.

Technical Summary

Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)

Assessment Status Rapid Review complete
HTA ID -
Drug Brentuximab vedotin
Brand Adcetris®
Indication Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension).
Assessment Process
Rapid review commissioned 07/02/2018
Rapid review completed 06/03/2018
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.

The HSE has approved reimbursement following confidential price negotiations, December 2022.

Brentuximab vedotin (Adcetris®) for CD30+ Hodgkins lymphoma. HTA ID: 19058

Assessment Status NCPE Assessment Process Complete
HTA ID 19058
Drug Brentuximab vedotin
Brand Adcetris®
Indication Treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant.
Assessment Process
Rapid review commissioned 30/12/2019
Rapid review completed 29/01/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 05/02/2020
Pre-submission consultation with Applicant 19/05/2020
Full submission received from Applicant 11/01/2021
Preliminary review sent to Applicant 12/07/2021
NCPE assessment re-commenced 06/08/2021
Factual accuracy sent to Applicant 24/09/2021
NCPE assessment re-commenced 30/09/2021
NCPE assessment completed 22/10/2021
NCPE assessment outcome The NCPE recommends that brentuximab vedotin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations, December 2022.

Brentuximab vedotin (Adcetris®). HTA ID: 21010

Assessment Status Rapid Review complete
HTA ID 21010
Drug Brentuximab vedotin
Brand Adcetris®
Indication In combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP) in combination for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
Assessment Process
Rapid review commissioned 24/03/2021
Rapid review completed 23/04/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin (Adcetris®)  compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations, December 2022.

Brexucabtagene Autoleucel (Tecartus®). HTA ID: 23045

Assessment Status NCPE Assessment Process complete
HTA ID 23045
Drug Brexucabtagene Autoleucel
Brand Tecartus®
Indication Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
Assessment Process
Rapid review commissioned 24/07/2023
Rapid review completed 10/08/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brexucabtagene autoleucel compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 31/08/2023
Pre-submission consultation with Applicant 09/10/2023
Full submission received from Applicant 18/01/2024
Preliminary review sent to Applicant 18/09/2024
NCPE assessment re-commenced 17/10/2024
Factual accuracy sent to Applicant 20/12/2024
NCPE assessment re-commenced 10/01/2025
NCPE assessment completed 23/01/2025
NCPE assessment outcome The NCPE recommends that brexu-cel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Brigatinib (Alunbrig®)

Assessment Status Rapid Review complete
HTA ID -
Drug Brigatinib
Brand Alunbrig®
Indication As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
Assessment Process
Rapid review commissioned 19/11/2018
Rapid review completed 11/12/2018
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations; June 2019

Brigatinib (Alunbrig®). HTA ID: 20031

Assessment Status Rapid Review complete
HTA ID 20031
Drug Brigatinib
Brand Alunbrig®
Indication As monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK-inhibitor.
Assessment Process
Rapid review commissioned 16/06/2020
Rapid review completed 06/08/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that brigatinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations; October 2020

Brimonidine (Mirvaso®)

Assessment Status Rapid Review complete
HTA ID -
Drug Brimonidine
Brand Mirvaso®
Indication Treatment of facial erythema of rosacea in adult patients.
Assessment Process
Rapid review commissioned 09/04/2014
Rapid review completed 06/05/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended

Brivaracetam (Briviact®)

Assessment Status Rapid Review complete
HTA ID -
Drug Brivaracetam
Brand Briviact®
Indication As adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Assessment Process
Rapid review commissioned 15/02/2016
Rapid review completed 22/03/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations.

Brodalumab (Kyntheum®)

Assessment Status Rapid Review complete
HTA ID -
Drug Brodalumab
Brand Kyntheum®
Indication Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 25/07/2017
Rapid review completed 29/08/2017
Rapid review outcome Full pharmacoeconomic assessment recommended at submitted price

The HSE has approved reimbursement following confidential price negotiations January 2018.

Brolucizumab (Beovu®). HTA ID: 20009

Assessment Status Rapid Review complete
HTA ID 20009
Drug Brolucizumab
Brand Beovu®
Indication Treatment of neovascular (wet) age-related macular degeneration.
Assessment Process
Rapid review commissioned 26/02/2020
Rapid review completed 07/04/2020
Rapid review outcome A full HTA is recommended to assess the clinical and cost effectiveness of brolucizumab compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.